By the same authors

From the same journal

From the same journal

Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs

Research output: Contribution to journalArticlepeer-review

Standard

Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs. / Bell, Andrew S.; Mills, James E.; Williams, Gareth P.; Brannigan, James A.; Wilkinson, Anthony J.; Parkinson, Tanya; Leatherbarrow, Robin J.; Tate, Edward W.; Holder, Anthony A.; Smith, Deborah F.

In: PLOS NEGLECTED TROPICAL DISEASES, Vol. 6, No. 4, e1625, 04.2012.

Research output: Contribution to journalArticlepeer-review

Harvard

Bell, AS, Mills, JE, Williams, GP, Brannigan, JA, Wilkinson, AJ, Parkinson, T, Leatherbarrow, RJ, Tate, EW, Holder, AA & Smith, DF 2012, 'Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs', PLOS NEGLECTED TROPICAL DISEASES, vol. 6, no. 4, e1625. https://doi.org/10.1371/journal.pntd.0001625

APA

Bell, A. S., Mills, J. E., Williams, G. P., Brannigan, J. A., Wilkinson, A. J., Parkinson, T., Leatherbarrow, R. J., Tate, E. W., Holder, A. A., & Smith, D. F. (2012). Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs. PLOS NEGLECTED TROPICAL DISEASES, 6(4), [e1625]. https://doi.org/10.1371/journal.pntd.0001625

Vancouver

Bell AS, Mills JE, Williams GP, Brannigan JA, Wilkinson AJ, Parkinson T et al. Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs. PLOS NEGLECTED TROPICAL DISEASES. 2012 Apr;6(4). e1625. https://doi.org/10.1371/journal.pntd.0001625

Author

Bell, Andrew S. ; Mills, James E. ; Williams, Gareth P. ; Brannigan, James A. ; Wilkinson, Anthony J. ; Parkinson, Tanya ; Leatherbarrow, Robin J. ; Tate, Edward W. ; Holder, Anthony A. ; Smith, Deborah F. / Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs. In: PLOS NEGLECTED TROPICAL DISEASES. 2012 ; Vol. 6, No. 4.

Bibtex - Download

@article{44ff3048f9dd4c17af03026889221088,
title = "Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs",
abstract = "Inhibition of N-myristoyltransferase has been validated pre-clinically as a target for the treatment of fungal and trypanosome infections, using species-specific inhibitors. In order to identify inhibitors of protozoan NMTs, we chose to screen a diverse subset of the Pfizer corporate collection against Plasmodium falciparum and Leishmania donovani NMTs. Primary screening hits against either enzyme were tested for selectivity over both human NMT isoforms (Hs1 and Hs2) and for broad-spectrum anti-protozoan activity against the NMT from Trypanosoma brucei. Analysis of the screening results has shown that structure-activity relationships (SAR) for Leishmania NMT are divergent from all other NMTs tested, a finding not predicted by sequence similarity calculations, resulting in the identification of four novel series of Leishmania-selective NMT inhibitors. We found a strong overlap between the SARs for Plasmodium NMT and both human NMTs, suggesting that achieving an appropriate selectivity profile will be more challenging. However, we did discover two novel series with selectivity for Plasmodium NMT over the other NMT orthologues in this study, and an additional two structurally distinct series with selectivity over Leishmania NMT. We believe that release of results from this study into the public domain will accelerate the discovery of NMT inhibitors to treat malaria and leishmaniasis. Our screening initiative is another example of how a tripartite partnership involving pharmaceutical industries, academic institutions and governmental/non-governmental organisations such as Medical Research Council and Wellcome Trust can stimulate research for neglected diseases.",
author = "Bell, {Andrew S.} and Mills, {James E.} and Williams, {Gareth P.} and Brannigan, {James A.} and Wilkinson, {Anthony J.} and Tanya Parkinson and Leatherbarrow, {Robin J.} and Tate, {Edward W.} and Holder, {Anthony A.} and Smith, {Deborah F.}",
year = "2012",
month = apr,
doi = "10.1371/journal.pntd.0001625",
language = "English",
volume = "6",
journal = "PLOS NEGLECTED TROPICAL DISEASES",
issn = "1935-2727",
publisher = "Public Library of Science",
number = "4",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs

AU - Bell, Andrew S.

AU - Mills, James E.

AU - Williams, Gareth P.

AU - Brannigan, James A.

AU - Wilkinson, Anthony J.

AU - Parkinson, Tanya

AU - Leatherbarrow, Robin J.

AU - Tate, Edward W.

AU - Holder, Anthony A.

AU - Smith, Deborah F.

PY - 2012/4

Y1 - 2012/4

N2 - Inhibition of N-myristoyltransferase has been validated pre-clinically as a target for the treatment of fungal and trypanosome infections, using species-specific inhibitors. In order to identify inhibitors of protozoan NMTs, we chose to screen a diverse subset of the Pfizer corporate collection against Plasmodium falciparum and Leishmania donovani NMTs. Primary screening hits against either enzyme were tested for selectivity over both human NMT isoforms (Hs1 and Hs2) and for broad-spectrum anti-protozoan activity against the NMT from Trypanosoma brucei. Analysis of the screening results has shown that structure-activity relationships (SAR) for Leishmania NMT are divergent from all other NMTs tested, a finding not predicted by sequence similarity calculations, resulting in the identification of four novel series of Leishmania-selective NMT inhibitors. We found a strong overlap between the SARs for Plasmodium NMT and both human NMTs, suggesting that achieving an appropriate selectivity profile will be more challenging. However, we did discover two novel series with selectivity for Plasmodium NMT over the other NMT orthologues in this study, and an additional two structurally distinct series with selectivity over Leishmania NMT. We believe that release of results from this study into the public domain will accelerate the discovery of NMT inhibitors to treat malaria and leishmaniasis. Our screening initiative is another example of how a tripartite partnership involving pharmaceutical industries, academic institutions and governmental/non-governmental organisations such as Medical Research Council and Wellcome Trust can stimulate research for neglected diseases.

AB - Inhibition of N-myristoyltransferase has been validated pre-clinically as a target for the treatment of fungal and trypanosome infections, using species-specific inhibitors. In order to identify inhibitors of protozoan NMTs, we chose to screen a diverse subset of the Pfizer corporate collection against Plasmodium falciparum and Leishmania donovani NMTs. Primary screening hits against either enzyme were tested for selectivity over both human NMT isoforms (Hs1 and Hs2) and for broad-spectrum anti-protozoan activity against the NMT from Trypanosoma brucei. Analysis of the screening results has shown that structure-activity relationships (SAR) for Leishmania NMT are divergent from all other NMTs tested, a finding not predicted by sequence similarity calculations, resulting in the identification of four novel series of Leishmania-selective NMT inhibitors. We found a strong overlap between the SARs for Plasmodium NMT and both human NMTs, suggesting that achieving an appropriate selectivity profile will be more challenging. However, we did discover two novel series with selectivity for Plasmodium NMT over the other NMT orthologues in this study, and an additional two structurally distinct series with selectivity over Leishmania NMT. We believe that release of results from this study into the public domain will accelerate the discovery of NMT inhibitors to treat malaria and leishmaniasis. Our screening initiative is another example of how a tripartite partnership involving pharmaceutical industries, academic institutions and governmental/non-governmental organisations such as Medical Research Council and Wellcome Trust can stimulate research for neglected diseases.

UR - http://www.scopus.com/inward/record.url?scp=84861212906&partnerID=8YFLogxK

U2 - 10.1371/journal.pntd.0001625

DO - 10.1371/journal.pntd.0001625

M3 - Article

C2 - 22545171

VL - 6

JO - PLOS NEGLECTED TROPICAL DISEASES

JF - PLOS NEGLECTED TROPICAL DISEASES

SN - 1935-2727

IS - 4

M1 - e1625

ER -